IPI-504 in NSCLC Patients With ALK Translocations
NCT01228435
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
3
Enrollment
OTHER
Sponsor class
Stopped
slow accrual
Conditions
Lung Cancer
Stage IIIb Lung Cancer
Stage IV Lung Cancer
Interventions
DRUG:
IPI-504
Sponsor
Massachusetts General Hospital
Collaborators
[object Object]
[object Object]